This site is intended for healthcare professionals

Roche announces collaboration with Atea Pharmaceuticals to develop AT 527, a potential oral treatment for COVID-19 patients.

Read time: 1 mins
Last updated:26th Oct 2020
Published:23rd Oct 2020
Roche and Atea Pharmaceuticals, Inc. announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT 527, Atea’s investigational oral direct-acting antiviral, to people around the globe.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest